NCT04874194View on ClinicalTrials.gov

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

September 16, 2024

Study Completion Date

September 16, 2024

Conditions
Hematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Biphenotypic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
Interventions
DRUG

Omacetaxine Mepesuccinate

Given SC

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT04874194 - Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | Biotech Hunter | Biotech Hunter